Ritlecitinib 100 mg for alopecia areata

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Mar 2025: Trial registered, NCT06873945
  2. 1 Apr 2025: Trial started, NCT06873945

The trials

NCT06873945: A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

State
Under way
Phase
Phase 3
People
674 planned
Started
1 Apr 2025
Primary completion
19 Mar 2028
Arms
Ritlecitinib 100 mg (open-label)
Results
None posted
  1. 13 Mar 2025: Trial registered
  2. 1 Apr 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.